Although Immunex Corp. shares dropped $9.31 last Monday in the wake of the New Year's Eve approval of G.D.Searle & Co.'s Celebrex celecoxib, IMNX believes its Enbrel etanercept soluble TNF inhibitor and the pharma company's COX-2 inhibitor will prove to be complementary in rheumatoid arthritis.

Celebrex, a nonsteroidal anti-inflammatory drug (NSAID), received FDA approval for the "relief of the signs and symptoms" of RA and osteoarthritis